Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Marco Aurelio Salvino, MD PhD, Ong Tee Chuan, MD, Alaa Elhaddad, MD PhD, Kudrat Abdulkadyrov, MD PhD, Jake Shortt, MD, Hang Quach, MD, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Lee-Yung Shih, MD, Anna G. Turkina, MD PhD, Luis Meillon, MD, Yu Jin, MS, Sadhvi Khanna, MS, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 344.

https://doi.org/10.1182/blood.V126.23.344.344

Published: 2015

Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD

Blood (2014) 124 (21): 4542.

https://doi.org/10.1182/blood.V124.21.4542.4542

Published: 2014

Journal Articles

Cytogenetics As a Prognostic Factor Of The Overall Survival (OS) Of Mexican Patients With Myelodysplastic Syndrome (MDS)

Maria Guadalupe Rodriguez-Gonzalez, MD, Yaneth Martinez-Ibarra, MD, Jorge Vela-Ojeda, MD, PhD, Kevin Nacho-Vargas, MD, Luis Meillon, MD, Yamile Fattel, MD, Julio Robledo, MD, MSc, Tonatiuh Romero-Salas, PhD, Moises Xolotl-Castillo, MD

Blood (2013) 122 (21): 5236.

https://doi.org/10.1182/blood.V122.21.5236.5236

Published: 2013

Journal Articles

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jeff H. Lipton, PhD, MD, Luis Meillon, MD, Vernon Louw, MD, Carolina Pavlovsky, MD, Lee-Yung Shih, MD, Yu Jin, Sandip Acharya, Richard C. Woodman, Timothy P. Hughes, MD, Anna G. Turkina, MD, PhD

Blood (2013) 122 (21): 4009.

https://doi.org/10.1182/blood.V122.21.4009.4009

Published: 2013

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Ricardo Pasquini, MD, Jorge Cortes-Franco, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Zhixiang Shen, MD, PhD, Luis Meillon, MD, Lidia Mongay, MD, PhD, MBA, Dawn F. Eng, Jim Wang, PhD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD

Blood (2009) 114 (22): 4267.

https://doi.org/10.1182/blood.V114.22.4267.4267

Published: 2009

Journal Articles

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Blood (2008) 112 (11): 4275.

https://doi.org/10.1182/blood.V112.11.4275.4275

Published: 2008

NARROW

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Cytogenetics As a Prognostic Factor Of The Overall Survival (OS) Of Mexican Patients With Myelodysplastic Syndrome (MDS)

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Email alerts

ASH Publications

American Society of Hematology

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Cytogenetics As a Prognostic Factor Of The Overall Survival (OS) Of Mexican Patients With Myelodysplastic Syndrome (MDS)

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only